The high-risk world of biotech investing is back in the spotlight after market darling Neuren delivered early investors more than $1 billion in paper profits in 18 months on the back of clinical trial results that helped it commercialise a drug for neurological disorder Rett syndrome in children.
Meanwhile, another ASX-listed biotech rollercoaster, Mesoblast, faces an August 2 date with destiny. That’s when the Food and Drug Administration in the United States will respond to Mesoblast’s request to have a stem-cell-based injectable treatment for acute-graft versus host disease in children approved for use.
Loading...
Tom Richardson writes and comments on markets including equities, debt, crypto, software, banking, payments, and regulation. He worked in asset management at Bank of New York Mellon and is a member of the CFA Society of the UK as a holder of the Investment Management Certificate. Connect with Tom on Twitter. Email Tom at tom.richardson@afr.com
